Progyny, Inc. (PGNY)
NASDAQ: PGNY · Real-Time Price · USD
23.42
-0.25 (-1.06%)
Sep 2, 2025, 4:00 PM - Market closed

Company Description

Progyny, Inc., a benefits management company, provides fertility, family building, and women’s health benefits solutions in the United States.

The company offers fertility benefits solutions, such as differentiated benefits plan design that includes smart cycle treatment bundle; personalized concierge-style member support services; and a selective network of fertility specialists.

It also offers Progyny Rx, an integrated pharmacy benefits solution that provides access to the medications needed during their treatment and offers care management services.

In addition, the company offers assistance service program where various services can be offered through a reimbursement program, including adoption, surrogacy, doula, and travel reimbursement when travel is required to receive medical services.

The company was formerly known as Auxogyn, Inc. and changed its name to Progyny, Inc. in 2015. Progyny, Inc. was incorporated in 2008 and is headquartered in New York, New York.

Progyny, Inc.
Progyny logo
CountryUnited States
Founded2008
IPO DateOct 25, 2019
IndustryHealthcare Plans
SectorHealthcare
Employees680
CEOPeter Anevski

Contact Details

Address:
1359 Broadway
New York, New York 10018
United States
Phone212 888 3124
Websiteprogyny.com

Stock Details

Ticker SymbolPGNY
ExchangeNASDAQ
Stock TypeCommon Stock
Fiscal YearJanuary - December
Reporting CurrencyUSD
IPO Price$13.00
CIK Code0001551306
CUSIP Number74340E103
ISIN NumberUS74340E1038
Employer ID27-2220139
SIC Code8090

Key Executives

NamePosition
Peter Anevski CPAChief Executive Officer and Director
David J. Schlanger J.D.Executive Chairman
Michael SturmerPresident
Allison SwartzExecutive Vice President, General Counsel and Secretary
Melissa B. CummingsChief Operating Officer
Steven LeistChief Technology Officer
James HartVice President of Investor Relations
Risa FisherChief Marketing Officer
Cassandra PrattChief Human Resources Officer
Julie StadlbauerChief Business Development Officer

Latest SEC Filings

DateTypeTitle
Aug 28, 2025144Filing
Aug 11, 2025144Filing
Aug 8, 202510-QQuarterly Report
Aug 7, 20258-KCurrent Report
Aug 6, 2025SCHEDULE 13GFiling
Jul 29, 2025SCHEDULE 13G/AFiling
Jul 8, 20258-KCurrent Report
Jun 11, 2025144Filing
Jun 3, 2025144Filing
May 28, 20258-KCurrent Report